ArticleFrontiers in bioengineering and biotechnology2026
Synergistic photothermal therapy of esophageal cancer using Pt@MOF@PSs nanozymes.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, esophageal cancer (EC) is the seventh most commonly diagnosed cancer and the sixth leading cause of cancer-related death. However, its treatment remains challenging due to significant obstacles. Photothermal therapy (PTT), a minimally invasive technique, has emerged as a promising method for tumor ablation. However, its efficacy is limited by low photothermal conversion efficiency and poor tissue penetration. To address these limitations, this study developed a metal-organic framework (MOF)-based nanozyme for the treatment of EC. In this system, the dye IR780, used for photothermal conversion, was encapsulated in liposomes and anchored onto the MOF nanozyme, resulting in a Pt@MOF@PSs construct that improved the aqueous stability of IR780. This multifunctional nanozyme showed tumor-targeting and synergistic therapeutic effects. After passive accumulation in EC tissues, Pt@MOF@PSs suppressed hypoxia and promoted reactive oxygen species (ROS) production by using the high H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.